Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase I/IIa study of TG6002 (VV TK-RR-FCU1) administered by intravenous (IV) infusions in combination with oral flucytosine (5-FC) in patients with advanced gastro-intestinal (GI) tumors

Trial Profile

A Phase I/IIa study of TG6002 (VV TK-RR-FCU1) administered by intravenous (IV) infusions in combination with oral flucytosine (5-FC) in patients with advanced gastro-intestinal (GI) tumors

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 04 Dec 2018

At a glance

  • Drugs TG 6002 (Primary) ; Flucytosine
  • Indications Colon cancer; Gastrointestinal cancer; Liver metastases
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Transgene
  • Most Recent Events

    • 17 Oct 2018 According to a Transgene media release, the first patient has been dosed at Centre Leon Berard (France).
    • 19 Sep 2018 According to a Transgene media release, Investigational New Drug applications have been granted in Belgium, France and Spain. First patient is expected to be treated in coming weeks. Prof. Philippe Cassier, Centre Leon Berard, Lyon (France), is the principal investigator of the trial.
    • 09 Aug 2018 Status changed from planning to recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top